本文選題：前列腺癌　切入點：骨轉(zhuǎn)移　出處：《中華男科學(xué)雜志》2017年03期 　論文類型：期刊論文

【摘要】：目的:本研究觀察低血清睪酮水平是否能獨立預(yù)測前列腺癌骨轉(zhuǎn)移的風險。方法:本研究納入標準為接受前列腺穿刺證實為前列腺癌,并進行骨掃描檢測的患者165例,患者年齡58~78(66.6±5.3)歲。所有患者在診斷為前列腺癌之前未接受過雄激素剝奪治療、化療、放射治療。我們收集患者的臨床資料包括:年齡、前列腺穿刺Gleason評分、血清性激素、前列腺特異抗原(PSA)和堿性磷酸酶(ALP)水平,其中血清標本在前列腺穿刺之前的清晨收集。根據(jù)骨掃描結(jié)果,將前列腺癌分為骨掃描組和非骨掃描組,通過單因素分析篩選出有差異的因子,并進行了多因素非條件回歸模型篩選出獨立預(yù)測因子。結(jié)果:165例前列腺癌患者納入本次研究,依據(jù)骨掃描結(jié)果分為前列腺癌骨轉(zhuǎn)移組和非骨轉(zhuǎn)移組。單因素分析結(jié)果顯示年齡(P=0.126)、黃體生成素(P=0.930)、卵泡刺激素(P=0.763)和雌二醇(P=0.256)在兩組之間并沒有統(tǒng)計學(xué)差異,而血清PSA(P0.001)、前列腺穿刺的Gleason評分(P0.001)、血清睪酮(P=0.013)及血清堿性磷酸酶(P0.001)在預(yù)測骨轉(zhuǎn)移有統(tǒng)計學(xué)意義。多因素分析結(jié)果顯示低血清睪酮(P=0.531)、前列腺穿刺Gleason評分(P=0.898)并不能作為獨立因子預(yù)測前列腺癌骨轉(zhuǎn)移的風險,而血清堿性磷酸酶(P0.001,OR=1.018[1.011~1.026])和血清PSA(P0.001,OR=1.029[1.015~1.044])是有效的預(yù)測前列腺癌骨轉(zhuǎn)移的風險因子。結(jié)論:低血清睪酮水平與前列腺癌骨轉(zhuǎn)移密切相關(guān),但不能成為有效的預(yù)測前列腺癌骨轉(zhuǎn)移的風險因子。
[Abstract]:Objective: to investigate whether low serum testosterone levels can independently predict the risk of bone metastasis in prostate cancer. Methods: 165 patients with prostate cancer confirmed by prostate puncture and examined by bone scan were included in this study. All patients were not treated with androgen deprivation, chemotherapy, radiotherapy before diagnosis of prostate cancer. Our clinical data included age, prostate puncture Gleason score, serum sex hormone. Serum samples were collected early in the morning before prostate puncture. According to the results of bone scan, prostate cancer was divided into bone scanning group and non bone scanning group. Independent predictors were screened by univariate analysis and multivariate non-conditional regression model. Results: 165 prostate cancer patients were included in this study. Univariate analysis showed that there was no significant difference between the two groups in age (P < 0. 126), luteinizing hormone (P) 0. 930, follicle stimulating hormone (P) 0. 763) and estradiol (P) 0. 256). However, serum PSA-P0.001, Gleason score of prostate puncture P0.001, serum testosterone P0.013) and serum alkaline phosphatase P0.001) had statistical significance in predicting bone metastasis. Multivariate analysis showed that low serum testosterone P0. 531, prostate puncture Gleason score P0. 898) could not be used as a predictor of bone metastasis. Independent factors predict the risk of bone metastasis in prostate cancer. Serum alkaline phosphatase (P0.001) and serum PSAP 0.001 OR1.029 [1.0151.044] are effective risk factors for predicting bone metastasis of prostate cancer. Conclusion: low serum testosterone level is closely associated with bone metastasis of prostate cancer. However, it is not an effective risk factor for predicting bone metastasis in prostate cancer.
【作者單位】： 九江學(xué)院;九江學(xué)院附屬醫(yī)院東院泌尿外科;南昌大學(xué)第一附屬醫(yī)院泌尿外科;
【基金】：江西省衛(wèi)生和計劃生育委員會科技支撐課題(20157083,20157084) 九江市支撐科技計劃(20140024)~~
【分類號】：R737.25

【相似文獻】

相關(guān)期刊論文 前10條

1 張星霖;張盛;;唑來磷酸治療骨轉(zhuǎn)移癌癥痛的療效觀察[J];中國疼痛醫(yī)學(xué)雜志;2006年02期

2 肖必文;乳腺癌術(shù)后骨轉(zhuǎn)移臨床分析[J];實用腫瘤雜志;2001年04期

3 黃劍,肖春容;以骨轉(zhuǎn)移為首發(fā)表現(xiàn)的肺癌2例[J];四川醫(yī)學(xué);2002年02期

4 陳麗敏;鄭弘宇;黃偉煒;;乳腺癌術(shù)后骨轉(zhuǎn)移的相關(guān)因素分析[J];福建醫(yī)藥雜志;2006年03期

5 ;2010年揚帆計劃,為更多骨轉(zhuǎn)移患者帶來福音(英文)[J];Chinese-German Journal of Clinical Oncology;2010年08期

6 劉云峰;;常規(guī)放療和低分割放療治療骨轉(zhuǎn)移止痛28例的效果分析[J];求醫(yī)問藥(下半月);2012年02期

7 樊英;丁曉燕;馬飛;袁們;張頻;王佳玉;李青;徐兵河;;三陰性乳腺癌首發(fā)骨轉(zhuǎn)移患者的臨床特征、治療及預(yù)后分析[J];中華臨床醫(yī)師雜志(電子版);2012年19期

8 申葉珍;孫文湘;賈曉s，

本文編號：1603001